Drug Approvals

FDA Approves Jaypirca for Mantle Cell Lymphoma Treatment on January 20, 2023

FDA Approves Jaypirca for Mantle Cell Lymphoma Treatment on January 20, 2023

What is Jaypirca prescribed for?   Jaypirca is prescribed to treat relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitor.  What is the name of the drug and what does it do? The name of the drug is Jaypirca, pronounced JAY-PIHR-KAA, (generic name: pirtobrutinib). It is a...

FDA Approves Fruzaqla: A New Hope for Metastatic Colorectal Cancer Patients, Approved November 8, 2023

FDA Approves Fruzaqla: A New Hope for Metastatic Colorectal Cancer Patients, Approved November 8, 2023

What is Fruzaqla prescribed for? Fruzaqla is prescribed for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy. What is Fruzaqla and what does it...

FDA Approves Loqtorzi for Advanced Nasopharyngeal Cancer on October 26, 2023

FDA Approves Loqtorzi for Advanced Nasopharyngeal Cancer on October 26, 2023

What is Loqtorzi prescribed for? Loqtorzi is prescribed to treat recurrent or metastatic nasopharyngeal carcinoma when used together with or following other therapies. What is Loqtorzi and what does it do? Loqtorzi, pronounced lok-tor-zee, (generic name: vonoprazan) is a medication recently approved by the FDA for treating nasopharyngeal carcinoma (NPC), a type of...

FDA Approves Omvoh for Ulcerative Colitis Treatment: A New Solution as of October 26, 2023

FDA Approves Omvoh for Ulcerative Colitis Treatment: A New Solution as of October 26, 2023

What is Omvoh prescribed for?    Omvoh is prescribed for the treatment of moderately to severely active ulcerative colitis in adults. What is Omvoh and what does it do? Omvoh, pronounced ahm-VOH, (generic name: mirikizumab-mrkz) is a medication recently approved to treat adults with moderate to severe ulcerative colitis, a chronic condition...

FDA Greenlights Agamree for Duchenne Muscular Dystrophy on October 26, 2023

FDA Greenlights Agamree for Duchenne Muscular Dystrophy on October 26, 2023

What is Agamree prescribed for?   Agamree is prescribed for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. What is Agamree and what does it do? Agamree,  pronounced ah gam' ree, (generic name: vamorolone), is a medication that was approved by the FDA to help treat Duchenne muscular dystrophy (DMD).  DMD...